Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr;28(4):040501.
doi: 10.1117/1.JBO.28.4.040501. Epub 2023 Apr 20.

Development of Pluoronic nanoparticles of fluorocoxib A for endoscopic fluorescence imaging of colonic adenomas

Affiliations

Development of Pluoronic nanoparticles of fluorocoxib A for endoscopic fluorescence imaging of colonic adenomas

Md Jashim Uddin et al. J Biomed Opt. 2023 Apr.

Abstract

Significance: Current white light colonoscopy suffers from many limitations that allow 22% to 32% of preneoplastic lesions to remain undetected. This high number of false negatives contributes to the appearance of interval malignancies, defined as neoplasms diagnosed between screening colonoscopies at a rate of 2% to 6%.

Aim: The shortcomings of today's white light-based colorectal cancer screening are addressed by colonoscopic fluorescence imaging of preneoplastic lesions using targeted fluorescent agents to enhance contrast between the lesion and the surrounding normal colonic epithelium.

Approach: We describe the development of Pluronic® nanoparticles of fluorocoxib A (FA), a fluorescent cyclooxygenase-2 (COX-2) inhibitor that enables targeted imaging of inflammation and cancer in numerous animal models, for endoscopic florescence imaging of colonic adenomas.

Results: We formulated FA, a fluorescent COX-2 inhibitor, or fluorocoxib negative control (FNC), a nontargeted fluorophore and a negative control for FA, in micellar nanoparticles of FDA approved Pluronic tri-block co-polymer using a bulk solvent evaporation method. This afforded FA-loaded micellar nanoparticles (FA-NPs) or FNC-loaded micellar nanoparticles (FNC-NPs) with the hydrodynamic diameters ( D h ) of 45.7 ± 2.5 nm and 44.9 ± 3.8 nm and the zeta potentials ( ζ ) of - 1.47 ± 0.3 mV and - 1.64 ± 0.5 mV , respectively. We intravenously injected B6;129 mice bearing colonic adenomas induced by azoxymethane and dextran-sodium sulfate with FA-loaded Pluronic nanoparticles (FA-NPs). The diffusion-mediated local FA release and its binding to COX-2 enzyme allowed for clear detection of adenomas with high signal-to-noise ratios. The COX-2 targeted delivery and tumor retention were validated by negligible tumor fluorescence detected upon colonoscopic imaging of adenoma-bearing mice injected with Pluronic nanoparticles of FNC or of animals predosed with the COX-2 inhibitor, celecoxib, followed by intravenous dosing of FA-NPs.

Conclusions: These results demonstrate that the formulation of FA in Pluronic nanoparticles overcomes a significant hurdle to its clinical development for early detection of colorectal neoplasms by fluorescence endoscopy.

Keywords: Fluorocoxib A; Pluronic® nanoparticles; colorectal adenomas; cyclooxygenase-2; fluorescence colonoscopy.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
(a) Chemical structure of FA and FNC. (b) Pluronic F127 polymeric micellar nanoparticle formulation of FA or FNC in CHCl3 and DPBS following gentle stirring at 25°C for 16 h in the dark.
Fig. 2
Fig. 2
(a) Representative white light and corresponding fluorescence colonoscopy images (static) of B6;129 mice bearing either colorectal adenomas or normal colon injected with Pluronic micellar nanoparticles of fluorocoxib A (FA-NPs, 0.5 mg/kg) or Pluronic micellar nanoparticles of fluorocoxib negative control (FNC-NPs, 0.5 mg/kg) via tail vein injections. In the COX-2 blocking control experiment, tumor bearing B6;129 mice received FA-NPs (0.5 mg/kg) 1 h after an intraperitoneal injection of celecoxib (10 mg/kg) to block binding of FA to the COX-2 active site. (b) ImageJ software was used for quantification of fluorescence intensity at the ROI of colonic adenomas versus adjacent normal colon epithelium (N.S., not significant). (c) COX-2 immunohistochemical staining of well-differentiated adenoma and adjacent normal colon (Video 1, MOV, 31.9 MB [URL: https://doi.org/10.1117/1.JBO.28.4.040501.s1]).

References

    1. Smith W. L., Garavito R. M., DeWitt D. L., “Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2,” J. Biol. Chem. 271(52), 33157–33160 (1996). 10.1074/jbc.271.52.33157 - DOI - PubMed
    1. Harris R. E., “Cyclooxygenase-2 (COX-2) and the inflammogenesis of cancer,” Subcell Biochem. 42, 93–126 (2007). 10.1007/1-4020-5688-5_4 - DOI - PubMed
    1. Hashemi Goradel N., et al. , “Cyclooxygenase-2 in cancer: a review,” J. Cell Physiol. 234(5), 5683–5699 (2018). 10.1002/jcp.27411 - DOI - PubMed
    1. Eberhart C. E., et al. , “Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas,” Gastroenterology 107(4), 1183–1188 (1994). 10.1016/0016-5085(94)90246-1 - DOI - PubMed
    1. Elder D. J., et al. , “Human colorectal adenomas demonstrate a size-dependent increase in epithelial cyclooxygenase-2 expression,” J. Pathol. 198(4), 428–434 (2002). 10.1002/path.1232 - DOI - PubMed

Publication types